>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
41 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Human Dendritic Cell-specific ICAM-3 Grabbing Non-integrin (DC-SIGN)/CD209 is a member of the C-type lectin family (1). The canonical DC-SIGN/CD209 isoform is a 46 kDa, 404 amino acid (aa) type II transmembrane protein (2). The extracellular region contains a Ca2+-dependent carbohydrate-binding lectin domain (2). Multiple human DC-SIGN/CD209 splice forms exist, generating both membrane-bound and soluble forms (3). DC-SIGN/CD209 is not well conserved between mouse and human, with the extracellular domain sharing only 63% aa identity. The DC-SIGN/CD209 lectin domain binds mannose oligosaccharides on pathogens including HIV as well as self glycoproteins including ICAMs (2, 4). DC-SIGN/CD209 binds to butyrophilin 2A1 and this interaction can be blocked by HIV pp120. DC-SIGN/CD209 is expressed on dendritic cells (DC) and inflammatory macrophages and contributes to antigen presentation (6, 7).
Liu, W. et al. (2004) J. Biol. Chem. 279:18748.
Curtis, B.M. et al. (1992) Proc. Natl. Acad. Sci. USA 89:8356.
Mummidi, S. et al. (2001) J. Biol. Chem. 276:33196.
Anthony, R.M. et al. (2008) Proc. Natl. Acad. Sci. USA 105:19571.
Malcherek, G. et al. (2007) J. Immunol. 179:3804.
Geijtenbeek, T.B. et al. (2000) Cell 100:575.
Garcia-Vallejo, J.J. and Y. van Kooyk (2013) Trends Immunol. 34:482.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Recombinant Human DC-SIGN/CD209 Protein, CF and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.